Year: 2026
Type: article
Abstract: Articles: Reducing Proteinuria – FDA Accelerates Approval of Sibeprenlimab FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss New First-Line Digital Treatment for Generalized Anxiety Disorder Ammoxetine: A Potential New Antidepressant For Major Depressive Extended-Release Buprenorphine Dosing in Individuals With High-Risk Opioid Use Managing Acute Agitation Without Injections: Oral Medications in the ED Prescription Stimulant Continuation in Pregnancy and Birth Outcomes Zoliflodacin - A New Treatment For Gonorrhea Intranasal Dexmedetomidine for Postoperative Sleep Quality After Gynecologic Laparoscopy FDA Approves Depemokimab, the First Twice-Yearly Biologic for Severe Eosinophilic Asthma Cancer Care Engineering Allogeneic CD7-Targeted CAR-T Cells Through Targeted Base Editing Implications of GLP-1 and SGLT-2 Therapy on Frailty Incretin-Based Therapy for AUD A Promising Relief from Prurigo Nodularis Developing Therapy for Transthyretin Amyloidosis with Cardiomyopathy Biomarker-Guided Cardioprotection During Anthracycline Therapy Evolocumab in Patients without a Previous Myocardial Infarction or Stroke A New Option for oHCM: FDA Approval of Aficamten Etripamil Nasal Spray: Evidence-Based Self-Treatment for PSVT Conversion
Author: Pacific RxTracts
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Keywords: drug approval, oral semaglutide, generalized anxiety disorder, buprenorphine, opioid use, acute agitation, stimulant medication, pregnancy, zoliflodacin, gonorrhea, dexmedetomidine, postoperative sleep, gynecologic laparoscopy, depemokimab, eosinophilic asthma, chimeric antigen receptor T cells, base editing, frailty, alcoholism, prurigo nodularis, transthyretin amyloidosis, cardiomyopathy, anthracycline cardiotoxicity, evolocumab, hypertriglyceridemia, aficamten, supraventricular tachycardia
Open Access status: green
OpenAlex ID: W7209679822
